PDCD1LG2 and non-small cell lung carcinoma: It is known from in vitro studies that ERBB1 inhibitors reduce the expression of immunotherapy biomarkers such as PD-L1 in NSCLC cells and tumors from kinase inhibitor resistant patients express low levels of PD-L1 and PD-L2 [43, 44, 45–46].